Metformin

Geroscience luminary, Dr. Nir Barzilai, appointed President of the Academy for Health and Lifespan Research

Retrieved on: 
Lundi, avril 22, 2024
FDA, TAME, Bangladesh Technical Education Board, Research, Dean, FAST, Ingeborg, Human, Public, Metformin, The New Science, Biology, Management

( @nirbarzilaiMD ) will serve as its new President, effective immediately.

Key Points: 
  • ( @nirbarzilaiMD ) will serve as its new President, effective immediately.
  • Co-founder and board member at the AHLR, Barzilai has been elected to lead by fellow members of the Academy, all of whom are geroscience experts with distinguished leadership roles in the field.
  • His vision and ambitions are bigger than himself and we look forward to him serving as President for all of us."
  • Dr. Nir Barzilai is a preeminent leader in geroscience, who has studied the genetics of exceptional longevity in humans and the biology of aging in model organisms and their targets.

American College of Physicians issues clinical recommendations for newer pharmacological treatments of adults with Type 2 diabetes

Retrieved on: 
Vendredi, avril 19, 2024
ACP, Mortality, MACP, Stroke, Annals of Internal Medicine, American College, Meta-analysis, Risk, DPP-4, Guideline, Development, Assessment, Type 2 diabetes, Type 2, GRADE, Patient, Diabetes, Myocardial infarction, Weight loss, Internal medicine, Hospital, Chronic kidney disease, Metformin, Hypoglycemia, Heart, Systematic review, Disease

BOSTON, April 19, 2024 /PRNewswire/ -- The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients' values and preferences, and costs. Newer Pharmacological Treatments in Adults with Type 2 Diabetes: A Clinical Guideline from the American College of Physicians was published today in Annals of Internal Medicine.

Key Points: 
  • Reviews evidence of newer medications, recommends adding to metformin
    BOSTON, April 19, 2024 /PRNewswire/ -- The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes.
  • Newer Pharmacological Treatments in Adults with Type 2 Diabetes: A Clinical Guideline from the American College of Physicians was published today in Annals of Internal Medicine.
  • ACP today released clinical recommendations for the use of newer treatments in adults with Type 2 diabetes.
  • This clinical guideline is based on a systematic review of the effectiveness and harms of newer pharmacological treatments for Type 2 diabetes.

Newly Discovered Essential Nutrient May Slow Our Aging Clocks

Retrieved on: 
Mardi, avril 16, 2024
Acarbose, Hope, C15:0, Health, Heart, AMPK, Research, TED (conference), Navy, LPE, DRS, DNA, Liver, Ageing, Liu, Therapy, Longevity, Metformin, SAN, Fertilizer

SAN DIEGO, April 16, 2024 /PRNewswire-PRWeb/ -- In a world where the quest for extending human longevity seems never-ending, groundbreaking research offers increasing hope. A recent peer-reviewed study by Liu et al. has shown an epigenetic link between C15:0 and a slower aging process.

Key Points: 
  • Thus, the key to any promising longevity molecule is its ability to slow our biological aging rates.
  • Researchers discovered that individuals with higher levels of C15:0 had evidence of slower biological aging rates.
  • C15:0 (pentadecanoic acid) is the first essential fatty acid to be discovered in over 90 years.
  • As we continue to unravel the mysteries of healthy aging, C15:0 continues to build momentum as a leading nutrient that can slow aging and extend our longevity.

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

Retrieved on: 
Lundi, avril 1, 2024
Diagnosis, Health, Regeneration, Learning, Glycated hemoglobin, Menin, C-peptide, Insulin, Diabetes, AUC, Patient, Fasting, MD, Metformin, Person, Cancer, Safety, A1C, DSM-IV codes, Pharmaceutical industry

REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced initial response data from the first two type 1 diabetes patients treated with BMF-219 in the ongoing Phase II study (COVALENT-112).

Key Points: 
  • “We are very excited to announce the initial response data from the first two type 1 diabetes patients enrolled in the COVALENT-112 study.
  • Both patients showed improvement in measures of beta-cell function after only 4 weeks of dosing with BMF-219.
  • The trial includes an open label portion for adults with type 1 diabetes up to 15 years since diagnosis.
  • It has been exciting to participate in this study and explore this new pathway for the benefit of our patients.

L-Nutra's Groundbreaking Study Revolutionizes Type 2 Diabetes Management Through Fasting Mimicking Nutrition Technology

Retrieved on: 
Jeudi, avril 4, 2024
Glycated hemoglobin, Metabolism, FMD, Type 2 diabetes, Disease, Insulin, Diabetes, Patient, Research, Fasting, Standard of care, Food, Doctor of Philosophy, Diet, Insulin resistance, Clinical trial, Type 2, Safety, Waist, BMI, Metformin, Movement, Prediabetes, Pharmaceutical industry

This randomized, controlled, assessor-blinded trial introduces a new paradigm in diabetes management, focusing on "glycemic management,'' a new metric used to measure efficacy by medication reduction.

Key Points: 
  • This randomized, controlled, assessor-blinded trial introduces a new paradigm in diabetes management, focusing on "glycemic management,'' a new metric used to measure efficacy by medication reduction.
  • Glycemic Management: FMD participants demonstrated superior glycemic management, with 53% showing improvement, compared to only 8% in the control group.
  • L-Nutra's patented and clinically backed nutrition technology food formulations are effective in supporting metabolism, cell renewal, and muscle protection by mimicking the reset and rejuvenation pathways of fasting.
  • "With the Fasting Mimicking Diet, we have successfully enhanced the natural rejuvenating power of fasting with food which has made the regression and remission of diabetes within every patient's reach.

Journal of Pharmaceutical Analysis (JPA) Studies Find Promising Drug Candidates

Retrieved on: 
Vendredi, mars 29, 2024
Hydralazine, Issue 1, DHT, Pigment, UBA52, Neuroregeneration, Prevalence, Apoptosis, PNI, Serum, Homeostasis, Patient, Ferroptosis, JPA, Neuron, HYD, Metformin, Type, Nerve, BPH, Hypopigmentation, EB, Depigmentation, Met, Oxidative stress, Iron, Pharmaceutical industry

XI'AN, China, March 29, 2024 /PRNewswire/ -- Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features three articles in which candidate compounds for treating complex disorders were successfully identified, alongside their detailed mechanisms of action.

Key Points: 
  • The first study investigated the use of metformin (Met), a drug used to manage type II diabetes, for treating benign prostate hyperplasia (BPH).
  • The article was published in Volume 14, Issue 1 of the journal in January 2024 .
  • Using the Drug Signatures Database, they identified hydralazine (HYD), a potent arterial vasodilator, as a potential UBA52 disruptor.
  • Further studies will hopefully clarify the intricate connections among cellular processes, diseases, and potential drugs, paving the way for precise and efficient therapies.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Jeudi, mars 7, 2024
Liver, School, Liraglutide, Metformin, SCM, GDF15, HKBU, Artesunate, Multimedia, Research, Blood, Obesity, FDA, Fatty liver disease, Exercise, Nausea, Food, GDNF, Trial of the century, Health, Human, Safety, GFRAL, Associate, Patient, Fasting, Insulin, Nature Communications, Tissue, Appetite, Hong Kong Baptist University, Mouse, Public, Pharmaceutical industry

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Jeudi, mars 7, 2024
Liver, School, Liraglutide, Metformin, SCM, GDF15, HKBU, Artesunate, Research, Blood, Obesity, FDA, Fatty liver disease, Exercise, Nausea, Food, GDNF, Trial of the century, Health, Human, Safety, GFRAL, Associate, Patient, Fasting, Insulin, Nature Communications, Tissue, Appetite, Hong Kong Baptist University, Mouse, Public, Pharmaceutical industry

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Retrieved on: 
Lundi, janvier 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Kidney, Metabolic acidosis, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Retrieved on: 
Lundi, janvier 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised